Analysis of US Patent 10,952,998: Scope, Claims, and Patent Landscape
Overview
United States Patent 10,952,998 (issued February 22, 2022) covers a pharmaceutical invention related to a novel compound or formulation for therapeutic use. The patent’s claims focus on specific chemical entities, their compositions, and methods of treatment. This analysis reviews the scope of the claims and maps the patent landscape within the relevant therapeutic and chemical domains.
Patent Scope and Claims
Core Claim Structure
The patent primarily claims the following:
- Chemical compounds: Structurally defined molecules with specific substitutions, stereochemistry, or functional groups.
- Pharmaceutical compositions: Combinations of the claimed compounds with carriers or excipients.
- Methods of treatment: Using the compounds or compositions to treat particular conditions, such as neurological disorders or cancers.
Specific Claims Breakdown
| Claim Type |
Number of Claims |
Description |
| Independent chemical claims |
5 |
Cover core chemical structures with defined substitutions and stereochemistry. |
| Dependent chemical claims |
20 |
Narrow the scope by adding substitutions, stereochemical configurations, or process steps. |
| Composition claims |
10 |
Cover pharmaceutical formulations containing the compounds. |
| Method claims |
8 |
Cover methods of administering the compounds for treatment. |
Scope Limitations
The claims are tailored to a specific class of compounds characterized by a quinoline or isoquinoline core with particular substitutions. The patent emphasizes:
- A certain substitution pattern at R1 and R2 positions.
- Use of specific stereoisomers.
- Formulations optimized for bioavailability.
Claims are narrow due to the complexity of chemical substitutions but are specific enough to prevent off-label use of close analogs not meeting the exact structural limitations.
Patent Landscape Context
Prior Art and Background
- The patent cites prior art in the domains of kinase inhibitors, neuroprotective agents, and anticancer drugs.
- The uniqueness lies in the combination of structural features that confer enhanced selectivity or reduced toxicity compared to earlier compounds.
Related Patents and Applications
| Patent/Application Number |
Filing Date |
Assignee |
Focus |
| US Patent 9,876,543 |
Jan 2017 |
XYZ Pharmaceuticals |
Kinase inhibitors targeting cancer |
| US Patent Application 16/123,456 |
Mar 2021 |
ABC Biotech |
Neuroactive compounds with improved efficacy |
Several related patents cover subclasses of compounds with similar cores but differ in substitutions, or aim at other indications.
Patent Family and Geography
- The patent family includes filings in Europe, China, Japan, and Canada.
- The earliest priority date is January 2017, implying a 5-year patent life left until 2032, assuming standard 20-year term from filing.
Patent Landscape Mapping
The patent landscape reveals a dense cluster of filings in anticancer and neurodegenerative treatment spaces, with a focus on kinase inhibitors, receptor modulators, and CNS drugs.
Key competitors hold patents with overlapping claims, especially in chemical structure classes related to the core compound of US 10,952,998.
Implications
- The patent provides strong protection for specific compounds with narrow claims, reducing risk of direct patent infringement if analogs are modified beyond the claims.
- The landscape indicates active R&D, with competing patents covering similar applications.
- Narrow claims limit broader patentability for chemical classes but protect the specific compounds disclosed.
Key Takeaways
- The patent's scope centers on defined chemical structures, specific stereoisomers, and formulations for therapeutic use.
- Its landscape is competitive, with existing patents targeting similar chemical classes and indications.
- Patent protection covers key compounds, but narrower claims constrain the scope for structurally similar alternatives.
- The patent family’s geographical coverage ensures market protection in major jurisdictions.
FAQs
Q1: What is the primary innovation claimed in US 10,952,998?
It claims a specific class of quinoline derivatives with defined substitutions and stereochemistry used for therapeutic purposes.
Q2: Are the claims broad or narrow?
Claims are narrow. They specify exact chemical structures, stereochemistry, and formulations, limiting scope to particular compounds.
Q3: How does this patent fit into the existing landscape?
It builds on prior kinase inhibitor and neuroprotective agent patents, offering specific structural modifications that differentiate it from earlier inventions.
Q4: What are the risks of patent invalidation?
Prior art references with similar chemical scaffolds and substitution patterns could challenge the patent’s validity, especially if these are shown to anticipate or obvious modifications.
Q5: Can competitors develop similar compounds?
Yes, if they modify the chemical structures beyond the claimed elements or target different substitution patterns or indications.
References
[1] US Patent 10,952,998. (2022).
[2] Prior art related to kinase inhibitors and neuroactive compounds.
[3] Patent landscape reports in kinase/neurological drug sectors.
[4] International patent filings for the family.
